Trial intelligence / Profile preview

Phase 3 open-label randomized study of ASP2215 versus salvage chemotherapy in relapsed or refractory FLT3-mutated acute myeloid leukemia

MOH_2017-05-07_000380Phase 3Completed

Sponsor

Astellas Pharma

Start

Dec 2015

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1